What is Iterative Health?
Iterative Health operates at the intersection of advanced technology and clinical practice, specializing in the development of artificial intelligence and machine learning solutions for gastrointestinal care. The company's core value proposition lies in its ability to enhance the accuracy of medical imaging and endoscopy procedures, providing physicians with real-time, data-driven insights that facilitate superior diagnostic decision-making. By addressing critical gaps in standard clinical workflows, Iterative Health is effectively transforming how healthcare providers detect and manage complex conditions, thereby expanding access to high-quality care across diverse medical environments. Its market position is bolstered by a robust portfolio of enterprise-grade software that integrates seamlessly into existing hospital infrastructure.
How much funding has Iterative Health raised?
Iterative Health has raised a total of $257M across 3 funding rounds:
Series A
$30M
Series B
$150M
Series C
$77M
Series A (2021): $30M with participation from Johnson & Johnson Innovation, Seae Ventures, Eli Lilly, Obvious Ventures, and Breyer Capital
Series B (2022): $150M led by Johnson & Johnson, Obvious Ventures, Insight Partners, Eli Lilly, Breyer Capital, and Clearlake Capital
Series C (2026): $77M supported by EDBI, Intrepid Growth Partners, The Obvious, GV, and Insight Partners
Key Investors in Iterative Health
EDBI
A global investor based in Singapore that focuses on high-growth technology sectors, aiming to catalyze industrial transformation through strategic capital deployment.
Intrepid Growth Partners
A growth equity firm that provides specialized financial support to entrepreneurs building innovative solutions within the artificial intelligence space.
The Obvious
A creative and design firm that provides strategic communication and visual asset development to help companies differentiate themselves in competitive markets.
What's next for Iterative Health?
With the successful closure of this major enterprise-level funding round, Iterative Health is poised to enter a new phase of rapid commercial expansion and product diversification. The strategic roadmap likely includes the scaling of its AI-driven diagnostic suite to reach a broader international market, alongside continued investment in R&D to refine its machine learning algorithms. As the company transitions from a growth-stage innovator to a foundational player in the healthtech ecosystem, the focus will shift toward deepening partnerships with major healthcare providers and regulatory bodies to ensure widespread adoption of its clinical decision support systems. This capital provides the necessary runway to sustain long-term innovation while maintaining a competitive edge in the rapidly evolving landscape of digital health.
See full Iterative Health company page
